This Week at FDA: Woodcock’s irreplaceable legacy and an averted shutdown
This Week at FDAJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyMedical DevicesPharmaceuticalsUnited StatesThis Week at FDAJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyMedical DevicesPharmaceuticalsUnited States